{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:55Z","timestamp":1793064415900,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijrobp.2025.12.065","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:09:25Z","timestamp":1768435765000},"page":"1130-1139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Outcomes of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer: Results From a Real-World Large Patient Cohort"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0650-1968","authenticated-orcid":false,"given":"Claire","family":"van Vliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyama U.","family":"Tetar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Bohoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cobussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M.","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Meijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeroen A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.M.","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Versteijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.065_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0002","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0003","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0007","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","article-title":"Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: Final results on patient-reported outcomes of a prospective phase 2 study","volume":"4","author":"Tetar","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0008","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0009","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic resonance-guided adaptive radiation therapy for prostate cancer: The first results from the MOMENTUM study-An international registry for the evidence-based introduction of magnetic resonance-guided adaptive radiation therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0010","article-title":"Stereotactic magnetic resonance-guided daily adaptive radiation therapy for localized prostate cancer: Acute and late patient-reported toxicity outcomes","volume":"9","author":"Nugent","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0011","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys Imaging Radiat. Oncol."},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0012","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0013","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2023.03.057","article-title":"Every-other-day versus once-a-week urethra-sparing prostate stereotactic body radiation therapy: 5-year results of a randomized phase 2 trial","volume":"117","author":"Zilli","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0014","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0019","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1007\/s00330-002-1389-z","article-title":"Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis","volume":"12","author":"Engelbrecht","year":"2002","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0020","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1016\/j.ejrad.2011.06.056","article-title":"Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria?","volume":"81","author":"Cornud","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0021","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1148\/radiol.2016152542","article-title":"Interobserver reproducibility of the PI-RADS version 2 lexicon: A multicenter study of six experienced prostate radiologists","volume":"280","author":"Rosenkrantz","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0022","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","article-title":"Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate cancer local staging and disease risk classification","volume":"147","author":"Soeterik","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0023","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0024","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-023-11430-z","article-title":"A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)","volume":"23","author":"Wolfe","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.065_bib0025","article-title":"Primary endpoint analysis of the phase 2 DESTINATION-MRL trial for patients with intermediate-risk prostate cancer [epub ahead of print.]","author":"Dassen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:22:52Z","timestamp":1782285772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0360301626000659"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.065","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Prostate Cancer: Results From a Real-World Large Patient Cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}